Bile Acid-Based Nanoparticles Enable Oral Insulin Absorption Through Active Intestinal Transport
Insulin-bile salt nanocomplex achieved 6.44% pharmacological availability via jejunal administration by exploiting the ASBT bile acid transporter for active intestinal absorption.
Quick Facts
What This Study Found
Insulin-SGDC nanocomplexes achieved 6.44% pharmacological availability via jejunal administration through ASBT-mediated active transport. Jejunal delivery was 17.89-fold more effective than colonic. Caco-2 permeability improved 6.36-fold vs. insulin solution.
Key Numbers
HIP of insulin + SGDC; markedly improved intestinal absorption via bile acid transporters vs free insulin.
How They Did This
Hydrophobic ion-pairing of insulin with sodium glycodeoxycholate. Optimization and characterization. Caco-2 permeability studies with endocytosis inhibitors. ASBT-transfected MDCK cells for transport confirmation. In vivo intrajejunal and intracolonic administration in rats.
Why This Research Matters
Replacing insulin injections with oral formulations would transform diabetes management for millions of patients. Exploiting an existing active transport system rather than trying to force passive absorption is an innovative strategy.
The Bigger Picture
Oral peptide delivery has been limited by the assumption that large molecules can't cross the intestinal wall. By leveraging existing biological transport systems (bile acid transporters), this approach opens a new paradigm for oral delivery of peptide drugs beyond insulin.
What This Study Doesn't Tell Us
Rat intrajejunal delivery doesn't replicate oral administration with gastric transit. 6.44% bioavailability, while improved, may not be sufficient for clinical use. Manufacturing scalability and stability need assessment. Human ASBT capacity and variability could affect performance.
Questions This Raises
- ?Can this bile acid transport approach achieve clinically useful oral insulin bioavailability?
- ?Would enteric coating allow oral capsule delivery targeting the jejunum?
- ?Could this platform be applied to other peptide drugs like GLP-1 agonists?
Trust & Context
- Key Stat:
- 6.44% pharmacological availability of oral insulin via bile acid transporter-mediated jejunal absorption
- Evidence Grade:
- Proof-of-concept with both in vitro mechanistic confirmation and in vivo pharmacological data. Promising but requires optimization for practical oral delivery.
- Study Age:
- Published in 2021. Oral insulin delivery continues to be one of the most active areas of peptide drug delivery research.
- Original Title:
- Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach.
- Published In:
- Journal of controlled release : official journal of the Controlled Release Society, 338, 644-661 (2021)
- Authors:
- Bashyal, Santosh(2), Seo, Jo-Eun(2), Choi, Young Wook(2), Lee, Sangkil
- Database ID:
- RPEP-05273
Evidence Hierarchy
Frequently Asked Questions
Why can't insulin be taken as a pill currently?
Insulin is a protein that gets destroyed by stomach acid and digestive enzymes, and the remaining fragments are too large to cross the intestinal wall. These nanoparticles protect insulin and use the body's own bile acid transport system to carry it across.
What is the ASBT transporter?
The apical sodium-dependent bile acid transporter (ASBT) is a dedicated protein in the intestinal wall that actively absorbs bile salts from digested food. By pairing insulin with bile salts, researchers hijacked this transport system to carry insulin along.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05273APA
Bashyal, Santosh; Seo, Jo-Eun; Choi, Young Wook; Lee, Sangkil. (2021). Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach.. Journal of controlled release : official journal of the Controlled Release Society, 338, 644-661. https://doi.org/10.1016/j.jconrel.2021.08.060
MLA
Bashyal, Santosh, et al. "Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach.." Journal of controlled release : official journal of the Controlled Release Society, 2021. https://doi.org/10.1016/j.jconrel.2021.08.060
RethinkPeptides
RethinkPeptides Research Database. "Bile acid transporter-mediated oral absorption of insulin vi..." RPEP-05273. Retrieved from https://rethinkpeptides.com/research/bashyal-2021-bile-acid-transportermediated-oral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.